

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 8-K

DUSA PHARMACEUTICALS INC
Form 8-K
May 20, 2004

FORM 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 20, 2004

DUSA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

NEW JERSEY
(State or other
jurisdiction of
incorporation)

0-19777
(Commission
File Number)

22-3103129
(IRS Employer
Identification
Number)

25 UPTON DRIVE
WILMINGTON, MASSACHUSETTS 01887
(Address of principal executive offices, including ZIP code)

(978) 657-7500
(Registrant's telephone number, including area code)

ITEM 5. OTHER EVENTS.

On May 20, 2004, DUSA Pharmaceuticals, Inc. ("DUSA") announced the initiation of a new multicenter Phase II clinical study using DUSA's Levulan(R) Photodynamic Therapy (PDT) for treatment of facial photodamage. DUSA also announced that it has signed agreements with Lumenis Inc. ("Lumenis") and Cynosure Corp. ("Cynosure") to include Lumenis' Quantum Intense Pulsed Light and Cynosure's PhotoGenica(R) V-Star(R) Long Pulse Dye Laser light sources in the study.

On May 20, 2004, DUSA also announced the filing of a Post-Effective Amendment to an existing Registration Statement on Form S-8 with the SEC.

ITEM 7. FINANCIAL STATEMENTS AND OTHER EXHIBITS.

[99.1] Press Release dated May 20, 2004.

[99.2] Press Release dated May 20, 2004.

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DUSA PHARMACEUTICALS, INC.

Dated: May 20, 2004

By: /s/ D. Geoffrey Shulman

D. Geoffrey Shulman, MD, FRCPC
President and Chief Executive Officer